Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

CANCER THERAPY

dMMR and thiopurines strand TP53 for ALL relapse

Nature Cancer volume 2, pages 777–779 (2021)Cite this article

Subjects

Drug resistance may pre-exist or arise during therapy, but how precisely cancer treatment itself influences these processes is a major gap in the understanding of therapy resistance in cancer. A study of acute lymphocytic leukemia now provides direct evidence of thiopurine-induced mutations in the gene encoding the tumor suppressor p53 that result in multi-drug-resistant relapse.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Clonal evolution in leukemia driven by thiopurine treatment.

References

  1. Freyer, D. R. et al. Blood 117, 3010–3015 (2011).

    Article  CAS  Google Scholar 

  2. Pulsipher, M. A. et al. Bone Marrow Transplant. 50, 1173–1179 (2015).

    Article  CAS  Google Scholar 

  3. Bhatla, T. et al. J. Pediatr. Hematol. Oncol. 36, 413–418 (2014).

    Article  CAS  Google Scholar 

  4. Ma, X. et al. Nat. Commun. 6, 6604 (2015).

    Article  CAS  Google Scholar 

  5. Yang, F. et al. Nat. Can. https://doi.org/10.1038/s43018-021-00230-8 (2021).

  6. Meyer, J. A. et al. Nat. Genet. 45, 290–294 (2013).

    Article  CAS  Google Scholar 

  7. Li, B. et al. Nat. Med. 21, 563–571 (2015).

    Article  CAS  Google Scholar 

  8. Mullighan, C. G. et al. Nature 471, 235–239 (2011).

    Article  CAS  Google Scholar 

  9. Evensen, N. A. et al. Haematologica 103, 830–839 (2018).

    Article  CAS  Google Scholar 

  10. Li, B. et al. Blood 135, 41–55 (2020).

    Article  Google Scholar 

  11. Waanders, E. et al. Blood Cancer Discov. 1, 96–111 (2020).

    Article  Google Scholar 

  12. Boot, A. et al. Genome Res. 28, 654–665 (2018).

    Article  CAS  Google Scholar 

  13. Alexandrov, L. B. et al. Nature 500, 415–421 (2013).

    Article  CAS  Google Scholar 

  14. Saliba, J. et al. Pediatr. Blood Cancer 67, e28306 (2020).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Perlmutter Cancer Center, NYU Grossman School of Medicine New York, New York, NY, USA

    Nikki A. Evensen & William L. Carroll

  2. Department of Pediatrics and Pathology, NYU Grossman School of Medicine, New York, NY, USA

    William L. Carroll

Authors
  1. Nikki A. Evensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William L. Carroll
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William L. Carroll.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Evensen, N.A., Carroll, W.L. dMMR and thiopurines strand TP53 for ALL relapse. Nat Cancer 2, 777–779 (2021). https://doi.org/10.1038/s43018-021-00248-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-021-00248-y

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer